Search research articles
Contact Us
Filters
Showing results (61-70 of 71) with videos related to
Page
of 8
Sort By:
Journal for Immunotherapy of Cancer
|
July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Mehmet Altan, Yan Wang, Juhee Song, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Nature Communications
|
May 2, 2024
Response of treatment-naive brain metastases to stereotactic radiosurgery
Chibawanye I Ene, Christina Abi Faraj, Thomas H Beckham, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 71) with videos related to
Sort By:
Page
of 8
Journal for Immunotherapy of Cancer
|
July 4, 2023
Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial
Mehmet Altan, Yan Wang, Juhee Song, et al.
Journal of Medicinal Chemistry
|
December 10, 2021
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor
Xiaolun Wang, Shelley Allen, James F Blake, et al.
Nature Medicine
|
October 10, 2022
Anti-tumor efficacy of a potent and selective non-covalent KRAS<sup>G12D</sup> inhibitor
Jill Hallin, Vickie Bowcut, Andrew Calinisan, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Nature Communications
|
May 2, 2024
Response of treatment-naive brain metastases to stereotactic radiosurgery
Chibawanye I Ene, Christina Abi Faraj, Thomas H Beckham, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Page
of 8